Petrelintide

Also known as: ZP8396

Status

In trials. Investigational. Phase 3 confirmed by Zealand Pharma and Roche in April 2026; first pivotal trial starting in the second half of 2026.

What it is

An amylin analogue — the same hormone family as cagrilintide — designed for weight management with a tolerability profile aimed at fewer of the gastrointestinal effects typical of GLP-1s.

Source

Zealand Pharma / Roche announcements

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.